Basic & Clinical Medicine ›› 2018, Vol. 38 ›› Issue (4): 578-582.

Previous Articles     Next Articles

Role of programmed cell death receptor 1 signaling pathway in cancer immunotherapy

Weipeng Xiong   

  • Received:2017-11-28 Revised:2018-01-17 Online:2018-04-05 Published:2018-03-27
  • Contact: Weipeng Xiong E-mail:xiongwp@yahoo.com

Abstract: Research in immunotherapy has achieved important progress in tumor treatments. Programmed cell death receptor 1 (PD-1) is mainly expressed on the T lymphocyte surface and serves as an important immune regulator. The interactions of PD-1 and its ligand, PD-L1, involve in tumor-induced immunosuppression. Some of the approved antibody drugs targeting PD-1/PD-L1 signaling showed significant clinical benefits.

Key words: tumor, immunotherapy, programmed cell death receptor 1, antibody drug